Stock AnalizUroGen Pharma Ltd. URGN
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
UroGen Pharma Ltd. (URGN) is a healthcare company listed in the US with a market value of about $1.3B. In the twelve months to September 30, 2026 it had revenue of $250M and net income of -$66M, a net margin of -26.3%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 56% a year, a 5-year average ROIC of -394%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 93% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $250M | $110M | $90M | $83M | $64M | $48M | $12M | $18000 | $1M | $8M | $18M |
| Net income | -$66M | -$153M | -$127M | -$102M | -$110M | -$111M | -$128M | -$105M | -$76M | -$20M | -$2M |
| Free cash flow | -$132M | -$163M | -$97M | -$77M | -$88M | -$86M | -$107M | -$71M | -$38M | -$10M | $3M |
| EPS (diluted) | $-1.31 | $-3.13 | $-2.59 | $-2.08 | $-2.24 | $-2.26 | $-2.62 | $-2.14 | $-1.54 | $-0.41 | $-0.04 |
| Net margin | -26.3% | -139.8% | -140.3% | -123.6% | -170.6% | -230.7% | -1088.9% | -584100.0% | -6707.2% | -245.2% | -11.1% |
| ROIC | — | -435.4% | -67.2% | -147.9% | -583.4% | -736.5% | -101.1% | -46.9% | -65.2% | -23.0% | 3.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $60.71, 132% above the current price; targets range from $54.00 to $75.00; the consensus rating is “Strong buy”; expected EPS is $-0.30 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is UroGen Pharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 93% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does UroGen Pharma pay a dividend?
Not currently.
Is UroGen Pharma a good stock to buy?
We do not give buy or sell advice. UroGen Pharma scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.